within subject standard deviation in fully replicate design if carry over effect is present [General Sta­tis­tics]

posted by Ankit Parikh – India, 2023-06-14 11:33 (341 d 19:09 ago) – Posting: # 23589
Views: 1,185

Hello Divyen!

❝ ❝ Cmax is due to the burst phase of release from the formulation however the plasma concentration required to produce therapeutic effect is very low i.e. < 5 % of Cmax and it remains in therapeutic range from Day 4 to 120 due to slow release of the product. It provides therapeutic effect for 4 months and then new injection has to be taken on day 120.

❝ This seems to be LAI and from initial post also a HVD?

Yes it is LAI.

❝ If by day 4- conc. are LT 5% of Cmax- then what is your half life? Why do you want to measure it for 120 days and the burst release doesn't have any toxicity impact? If even product name can not be shared- then it is difficult to be answered from very few details.

It is Leuprolide 30 mg 4-month injection. Since it is continuously released and as per OGD, AUC7-t is the primary PK parameter, we need to collect the sample for 112 days. Half-life doesn't matter for this continuous release product.

So how to calculate Swr when unequal carryover effect is present in full replicate study design?


Complete thread:

UA Flag
 Admin contact
23,033 posts in 4,835 threads, 1,647 registered users;
51 visitors (0 registered, 51 guests [including 6 identified bots]).
Forum time: 06:42 CEST (Europe/Vienna)

Give me a fruitful error any time, full of seeds, bursting with its own corrections.
You can keep your sterile truth for yourself.    Vilfredo Pareto

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz